Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus

Abstract

BackgroundLipoprotein-associated phospholipase A2 (Lp-PLA2) is closely related to the development of cardiovascular diseases, and the association between Lp-PLA2 and lower extremity arterial disease (LEAD) in type 2 diabetes mellitus (T2DM) is inconsistent among previous studies. Thus, the present study aimed to investigate whether the increase in Lp-PLA2 is related to the occurrence of LEAD in patients with T2DM. MethodsA total of 519 patients with T2DM (173 patients with LEAD and 346 patients without LEAD) were enrolled in this study. The demographics, medical history, serum lipids, glycosylated hemoglobin, Lp-PLA2, and ankle-brachial index (ABI) were recorded and analyzed. ResultsThe diabetes duration, prevalence of female, prevalence of hypertension, and Lp-PLA2 concentration in the LEAD group were significantly higher than those in the non-LEAD group (duration of diabetes: 15 [10–20] vs 8 [2–12] years, prevalence of female: 49.13% vs 38.73%, prevalence of hypertension: 58.38% vs 38.11%, Lp-PLA2: 145 [108–178] vs 125 [107–138] ng/ml, p < 0.05). Lp-PLA2 was negatively correlated with ABI (r = −0.308, p < 0.001). Results of multivariate logistic regression analysis showed that serum Lp-PLA2 was an independent factor for the development of LEAD (odds ratio: 1.018 [1.007–1.029], P = 0.001). ConclusionsIncreased serum Lp-PLA2 concentrations are associated with LEAD in patients with T2DM. They are an independent risk factor for the occurrence of LEAD.